156 related articles for article (PubMed ID: 33127459)
1. Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin.
Sakr AA; Ahmed AE; Abd El-Maksoud MDE; Gamal A; El-Garem H; Ahmed OM
Infect Genet Evol; 2020 Dec; 86():104606. PubMed ID: 33127459
[TBL] [Abstract][Full Text] [Related]
2. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study.
Grzegorzewska AE; Mostowska A; Świderska MK; Marcinkowski W; Stolarek I; Figlerowicz M; Jagodziński PP
BMC Infect Dis; 2021 Jan; 21(1):102. PubMed ID: 33482747
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Thymine--Adenine Dinucleotide Repeat, IL28B and IFNL4 in Thai Population and Correlation with Spontaneous Clearance and Treatment Outcome of Hepatitis C Infection.
Thong VD; Wasitthankasem R; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
PLoS One; 2015; 10(5):e0125400. PubMed ID: 25938236
[TBL] [Abstract][Full Text] [Related]
6. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
7. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.
Meissner EG; Bon D; Prokunina-Olsson L; Tang W; Masur H; O'Brien TR; Herrmann E; Kottilil S; Osinusi A
J Infect Dis; 2014 Jun; 209(11):1700-4. PubMed ID: 24367041
[TBL] [Abstract][Full Text] [Related]
8. IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6.
Akkarathamrongsin S; Thong VD; Payungporn S; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
J Med Virol; 2014 Sep; 86(9):1482-90. PubMed ID: 24782280
[TBL] [Abstract][Full Text] [Related]
9. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
Iqbal S; Yousuf MH; Yousaf MI
World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
[TBL] [Abstract][Full Text] [Related]
10. The impact of genetic variations in sofosbuvir metabolizing enzymes and innate immunity mediators on treatment outcome in HCV-infected patients.
Ibrahim MK; AbdElrahman M; Bader El Din NG; Tawfik S; Abd-Elsalam S; Omran D; Barakat AZ; Farouk S; Elbatae H; El Awady MK
Microb Pathog; 2022 Jan; 162():105311. PubMed ID: 34843922
[TBL] [Abstract][Full Text] [Related]
11. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
[TBL] [Abstract][Full Text] [Related]
12. Prediction of sofosbuvir response using interleukin-6 serum level and single nucleotide polymorphism of interferon lambda- 4.
Saafan AE; Abobaker A; Abbas MS; El-Gendy A
J Infect Dev Ctries; 2020 Jan; 14(1):80-88. PubMed ID: 32088688
[TBL] [Abstract][Full Text] [Related]
13. Prediction of response to sofosbuvir-based therapy using serum interleukin-12 and single nucleotide polymorphism of the interleukin 28B gene as predictive factors in HCV positive genotype-4 patients.
Mohamed Abdelnajid D; Elmowafy AY; Rostaing L; Elrakaiby MT
Medicine (Baltimore); 2023 Jul; 102(28):e34125. PubMed ID: 37443472
[TBL] [Abstract][Full Text] [Related]
14. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance.
O'Brien TR; Pfeiffer RM; Paquin A; Lang Kuhs KA; Chen S; Bonkovsky HL; Edlin BR; Howell CD; Kirk GD; Kuniholm MH; Morgan TR; Strickler HD; Thomas DL; Prokunina-Olsson L
J Hepatol; 2015 Nov; 63(5):1103-10. PubMed ID: 26186989
[TBL] [Abstract][Full Text] [Related]
15. IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation.
Fernández-Carrillo C; Coto-Llerena M; González P; Crespo G; Mensa L; Caro-Pérez N; Gambato M; Navasa M; Forns X; Pérez-del-Pulgar S
J Clin Virol; 2014 Oct; 61(2):282-5. PubMed ID: 25130512
[TBL] [Abstract][Full Text] [Related]
16. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
[TBL] [Abstract][Full Text] [Related]
17. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
18. The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3.
Holmes JA; Congiu M; Bonanzinga S; Sandhu MK; Kia YH; Bell SJ; Nguyen T; Iser DM; Visvanathan K; Sievert W; Bowden DS; Desmond PV; Thompson AJ
Aliment Pharmacol Ther; 2015 Aug; 42(3):296-306. PubMed ID: 26032235
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.
Sticchi L; Di Biagio A; Sartini M; Rappazzo E; Nicolini LA; Cenderello G; Valle C; Azzola E; Grasso A; De Leo P; Boldrini A; Setti M; Prinapori R; Lorusso C; Bruzzone B; Icardi G;
New Microbiol; 2015 Oct; 38(4):499-509. PubMed ID: 26485009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
